Intravenous high-dose anakinra drops venous thrombosis and acute coronary syndrome in severe and critical COVID-19 patients: a propensity score matched study

• Published in: Scientific reports 2024-05, Vol.14 (1), p.12369-14, Article 12369
• Main Authors: Çakmak, Ramazan, Yüce, Servet, Ay, Mustafa, Uyar, Muhammed Hamdi, Kılıç, Muhammed İkbal, Bektaş, Murat
• Format: Article
• Language: English
• Subjects: 631/250; 631/326; 692/4023; Acute coronary syndrome; Acute Coronary Syndrome - complications; Acute Coronary Syndrome - drug therapy; Acute coronary syndromes; Administration, Intravenous; Aged; Anakinra; Cardiovascular disease; Cardiovascular diseases; Comorbidity; Coronary artery disease; COVID-19; COVID-19 - complications; COVID-19 - mortality; COVID-19 Drug Treatment; Diabetes mellitus; Female; Heart diseases; Humanities and Social Sciences; Humans; Hyperinflammation; Hypertension; Inflammasome; Interleukin 1 receptor antagonist; Interleukin 1 Receptor Antagonist Protein - administration & dosage; Interleukin 1 Receptor Antagonist Protein - adverse effects; Interleukin 1 Receptor Antagonist Protein - therapeutic use; Intravenous administration; Male; Middle Aged; multidisciplinary; Observational studies; Population studies; Propensity Score; Retrospective Studies; SARS-CoV-2 - isolation & purification; Science; Science (multidisciplinary); Stroke; Survival; Survival analysis; Thromboembolism; Thrombosis; Turkey - epidemiology; Venous Thrombosis - drug therapy; Venous Thrombosis - etiology
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-62079-y

In our study, we aimed to evaluate the effect of high-dose intravenous anakinra treatment on the development of thrombotic events in severe and critical COVID-19 patients. This retrospective observational study was conducted at a tertiary referral center in Aksaray, Turkey. The study population consisted of two groups as follows; the patients receiving high-dose intravenous anakinra (anakinra group) added to background therapy and the patients treated with standard of care (SoC) as a historical control group. Age, gender, mcHIS scores, and comorbidities such as diabetes mellitus, hypertension, and coronary heart disease of the patients were determined as the variables to be matched. We included 114 patients in SoC and 139 patients in the Anakinra group in the study. Development of any thromboembolic event (5% vs 12.3%, p = 0.038; OR 4.3) and PTE (2.9% vs 9.6%, p = 0.023; OR 5.1) were lower in the Anakinra group than SoC. No patient experienced cerebrovascular accident and/or clinically evident deep venous thrombosis both in two arms. After 1:1 PS matching, 88 patients in SoC and 88 patients in the Anakinra group were matched and included in the analysis. In survival analysis, the development of any thromboembolic event, pulmonary thromboembolism, and acute coronary syndrome (ACS) were higher in SoC compared to Anakinra. Survival rate was also lower in patients with SoC arm than Anakinra in patients who had any thromboembolic event as well as ACS. In our study, the development of thrombosis was associated with hyperinflammation in patients with severe and critical COVID-19. Intravenous high-dose anakinra treatment decreases both venous and arterial events in patients with severe and critical COVID-19.